AI Article Synopsis

  • Platelets play a significant role in allergic asthma and aspirin-exacerbated respiratory disease (AERD) by being activated and influencing inflammatory responses.
  • The study found that the GLP-1 receptor (GLP-1R) agonist liraglutide reduced platelet activation and airway resistance in a mouse model of AERD, indicating its potential therapeutic benefits.
  • Liraglutide showed promise in inhibiting platelet activation in both mice and human patients with AERD, suggesting that targeting the GLP-1R could be a new strategy for managing asthma-related inflammation.

Article Abstract

Platelets are key contributors to allergic asthma and aspirin-exacerbated respiratory disease (AERD), an asthma phenotype involving platelet activation and IL-33-dependent mast cell activation. Human platelets express the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R agonists decrease lung IL-33 release and airway hyperresponsiveness in mouse asthma models. We hypothesized that GLP-1R agonists reduce platelet activation and downstream platelet-mediated airway inflammation in AERD. GLP-1R expression on murine platelets was assessed using flow cytometry. We tested the effect of the GLP-1R agonist liraglutide on lysine-aspirin (Lys-ASA)-induced changes in airway resistance, and platelet-derived mediator release in a murine AERD model. We conducted a prospective cohort study comparing the effect of pretreatment with liraglutide or vehicle on thromboxane receptor agonist-induced in vitro activation of platelets from patients with AERD and nonasthmatic controls. GLP-1R expression was higher on murine platelets than on leukocytes. A single dose of liraglutide inhibited Lys-ASA-induced increases in airway resistance and decreased markers of platelet activation and recruitment to the lung in AERD-like mice. Liraglutide attenuated thromboxane receptor agonist-induced activation as measured by CXCL7 release in plasma from patients with AERD and CD62P expression in platelets from both patients with AERD (n = 31) and nonasthmatic, healthy controls (n = 11). Liraglutide, a Food and Drug Administration-approved GLP-1R agonist for treatment of type 2 diabetes and obesity, attenuates in vivo platelet activation in an AERD murine model and in vitro activation in human platelets in patients with and without AERD. These data advance the GLP-1R axis as a new target for platelet-mediated inflammation warranting further study in asthma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842986PMC
http://dx.doi.org/10.4049/jimmunol.2300102DOI Listing

Publication Analysis

Top Keywords

platelet activation
20
patients aerd
16
platelets patients
12
activation
9
glucagon-like peptide-1
8
peptide-1 receptor
8
aspirin-exacerbated respiratory
8
respiratory disease
8
aerd
8
activation human
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!